INVO Fertility S-1: FNL to Resell 8.3M Shares, IVF Refocuses on Clinics

TL;DR

**INVO Fertility's S-1 is a red flag for existing shareholders, as a major holder is dumping 8.3 million shares, signaling potential dilution and price pressure on IVF.**

AI Summary

INVO Fertility, Inc. (IVF) filed an S-1 on October 14, 2025, for the resale of up to 8,345,774 shares of common stock by Five Narrow Lane LP (FNL). These shares consist of 770,973 shares from an Inducement Warrant exercised on April 30, 2025, and 7,574,801 shares from the conversion of Series C-2 Non-Voting Convertible Preferred Stock. The company will not receive proceeds from the stock sale, but may receive up to $344,000 from FNL's warrant exercise. INVO Fertility has strategically shifted from a medical device company to a healthcare services provider, focusing on acquiring and operating fertility clinics, including its two INVO Centers and one IVF clinic (Wisconsin Fertility Institute acquired August 10, 2023). A key business change was the October 2024 acquisition of NAYA Therapeutics, Inc., followed by an 80.1% divestiture in May 2025 to refocus on fertility. The company's proprietary INVOcell® device, which facilitates intravaginal culture (IVC), remains part of its offerings, aiming to provide a lower-cost alternative to traditional IVF. The last reported sale price for IVF common stock on Nasdaq was $0.7283 per share on October 13, 2025. The offering involves significant dilution risk, as the 8,345,774 shares represent a substantial portion compared to the 5,624,012 shares outstanding as of October 13, 2025, potentially impacting market price.

Why It Matters

This S-1 filing signals a significant potential increase in the public float for INVO Fertility, as Five Narrow Lane LP plans to sell up to 8,345,774 shares, which could exert downward pressure on the stock price for existing investors. The company's strategic pivot to a clinic-based model, exemplified by the Wisconsin Fertility Institute acquisition, aims to expand access to assisted reproductive technology and increase revenue per fertility cycle from hundreds to thousands of dollars. However, the substantial number of shares being registered for resale, combined with the company's relatively small outstanding share count of 5,624,012 as of October 13, 2025, introduces considerable dilution risk. This move positions INVO Fertility more directly against established fertility clinic networks, requiring successful integration and expansion to justify its valuation.

Risk Assessment

Risk Level: high — The offering involves a high degree of risk due to the potential for significant dilution and downward pressure on the stock price. The Selling Stockholder, Five Narrow Lane LP, is offering up to 8,345,774 shares, which is substantially more than the 5,624,012 shares of common stock outstanding as of October 13, 2025. This large volume of shares entering the market could adversely affect the market price of INVO Fertility's Common Stock, as explicitly stated in the 'Risk Factors' section.

Analyst Insight

Investors should exercise extreme caution and consider the potential for significant share price volatility and dilution. Given the large volume of shares being registered for resale by Five Narrow Lane LP, current shareholders might consider reducing their exposure, while prospective investors should await a clearer picture of market absorption and the company's operational performance post-dilution.

Key Numbers

• 8,345,774 — Shares of Common Stock (Maximum shares offered by the Selling Stockholder, representing potential dilution)
• $0.7283 — Last reported sale price per share (Common Stock price on Nasdaq as of October 13, 2025)
• 5,624,012 — Shares of Common Stock outstanding (As of October 13, 2025, prior to the offering)
• $344,000 — Potential proceeds to INVO Fertility (From the exercise of the Inducement Warrant by FNL)
• 770,973 — Shares from Inducement Warrant (Part of the shares offered by FNL, issued April 30, 2025)
• 7,574,801 — Shares from Series C-2 Preferred conversion (Part of the shares offered by FNL)
• 13,969,786 — Shares of Common Stock to be outstanding (After this offering, assuming full conversion and exercise by FNL)
• October 2024 — Acquisition date (INVO Fertility acquired NAYA Therapeutics, Inc.)
• May 2025 — Divestiture date (INVO Fertility divested 80.1% of NAYA Therapeutics, Inc.)
• August 10, 2023 — Acquisition date (INVO Fertility acquired Wisconsin Fertility Institute)

Key Players & Entities

• INVO Fertility, Inc. (company) — Registrant and healthcare services and technology company
• IVF (company) — Ticker symbol for INVO Fertility, Inc.
• Five Narrow Lane LP (company) — Selling Stockholder offering up to 8,345,774 shares
• Steve Shum (person) — Chief Executive Officer of INVO Fertility, Inc.
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Nasdaq Capital Market (company) — Stock exchange where IVF common stock is listed
• Wisconsin Fertility Institute (company) — IVF clinic acquired by INVO Fertility on August 10, 2023
• NAYA Therapeutics, Inc. (company) — Clinical-stage oncology and autoimmune technology company acquired in October 2024 and 80.1% divested in May 2025
• INVOcell® (company) — Proprietary medical device for intravaginal culture (IVC)
• $344,000 (dollar_amount) — Maximum proceeds INVO Fertility may receive from Inducement Warrant exercise

FAQ

Risk Factors

• Dilution from Selling Stockholder Shares [high — financial]: The resale of up to 8,345,774 shares by Five Narrow Lane LP (FNL) represents a significant dilution risk. These shares, comprising 770,973 from an Inducement Warrant and 7,574,801 from Series C-2 Preferred conversion, are substantially more than the 5,624,012 shares outstanding as of October 13, 2025. This could negatively impact the market price per share.
• Business Model Transition Challenges [medium — operational]: INVO Fertility is undergoing a strategic shift from a medical device company to a healthcare services provider, focusing on clinic acquisitions. The recent acquisition of Wisconsin Fertility Institute in August 2023 and the prior acquisition and subsequent partial divestiture of NAYA Therapeutics, Inc. (October 2024 acquisition, May 2025 80.1% divestiture) indicate a period of strategic realignment and integration challenges.
• Competition in Fertility Services [medium — market]: The company operates in the competitive fertility services market, offering its INVOcell® device as a lower-cost alternative to traditional IVF. Success depends on market adoption and differentiation against established IVF providers and emerging technologies.
• Regulatory Compliance for Medical Devices and Services [medium — regulatory]: As a provider of fertility services and a manufacturer of the INVOcell® device, INVO Fertility is subject to stringent regulatory oversight from bodies like the FDA and CMS. Compliance with evolving regulations for medical devices and healthcare services is critical for continued operation and market access.
• Dependence on Selling Stockholder [low — financial]: The company's financial activities related to this S-1 filing are primarily driven by the resale of shares by Five Narrow Lane LP. While INVO Fertility may receive up to $344,000 from FNL's warrant exercise, the primary purpose of the filing is not to raise capital for the company.

Industry Context

The fertility services industry is experiencing growth driven by increasing awareness, delayed childbearing, and advancements in assisted reproductive technologies. INVO Fertility operates within this landscape, aiming to differentiate itself with its INVOcell® device offering a potentially more accessible and cost-effective alternative to traditional IVF. The market includes established IVF clinics, specialized fertility centers, and companies developing innovative technologies.

Regulatory Implications

INVO Fertility faces significant regulatory scrutiny due to its medical device (INVOcell®) and healthcare services operations. Compliance with FDA regulations for devices and state/federal regulations for fertility clinics is paramount. Changes in healthcare policy or stricter enforcement could impact the company's ability to operate and market its products and services.

What Investors Should Do

1. Monitor share price and trading volume post-offering.
2. Evaluate the company's clinic acquisition and integration strategy.
3. Assess the market adoption and competitive positioning of INVOcell®.
4. Review future S-1 filings or 10-K/10-Q reports for updated financial performance.

Key Dates

• 2025-10-14: S-1 Filing for Resale of Shares — Initiates the process for Five Narrow Lane LP to sell a substantial number of shares, highlighting potential dilution for existing shareholders.
• 2025-05-01: 80.1% Divestiture of NAYA Therapeutics, Inc. — Indicates a strategic pivot to refocus on core fertility operations after a recent acquisition.
• 2025-04-30: Inducement Warrant Exercise — Resulted in the issuance of 770,973 shares, now part of the resale offering.
• 2024-10-01: Acquisition of NAYA Therapeutics, Inc. — Marked an expansion into new therapeutic areas, later partially divested.
• 2023-08-10: Acquisition of Wisconsin Fertility Institute — Demonstrates INVO Fertility's strategy to grow its healthcare services segment by acquiring established clinics.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and the securities being offered. (This filing details the resale of shares by a major stockholder, highlighting potential dilution and the company's strategic shifts.)

Inducement Warrant

A warrant issued to an investor or employee as an incentive, often in connection with a financing round or employment agreement, to encourage participation or retention. (The exercise of an Inducement Warrant by Five Narrow Lane LP is a source of shares for the current resale offering.)

Series C-2 Non-Voting Convertible Preferred Stock

A class of preferred stock that carries specific rights, such as conversion into common stock, but does not grant voting rights. 'Series C-2' indicates a specific issuance within a preferred stock series. (The conversion of these preferred shares into common stock is a primary source of the shares being offered for resale.)

Intravaginal Culture (IVC)

A method of culturing embryos within a specialized device placed inside the vaginal cavity, as opposed to traditional laboratory incubators. (This is the core technology behind INVO Fertility's INVOcell® device, positioned as a lower-cost alternative to standard IVF.)

Resale of Securities

The sale of securities that are already outstanding, typically by existing shareholders, rather than the issuance of new securities by the company itself. (This S-1 filing pertains to the resale of shares by Five Narrow Lane LP, meaning INVO Fertility will not receive proceeds from the majority of the shares being sold.)

Year-Over-Year Comparison

This S-1 filing is primarily for the resale of shares by a major stockholder, Five Narrow Lane LP, and does not represent a primary capital raise for INVO Fertility. Therefore, direct year-over-year comparisons of key financial metrics like revenue growth or margin changes are not applicable based on this document alone. The filing does highlight significant strategic shifts, including the acquisition and partial divestiture of NAYA Therapeutics, Inc., and the acquisition of Wisconsin Fertility Institute, indicating operational changes rather than direct financial performance evolution from a prior filing.

Key Financial Figures

• $0.0001 — r the “Company”), par value $0.0001 per share (the “Common Stock&rdqu
• $344,000 — s by FNL. However, we may receive up to $344,000 upon FNL’s exercise of the Induce
• $0.7283 — orted on Nasdaq on October 13, 2025 was $0.7283 per share. Investing in our securitie
• $341,438 — ceive aggregate gross proceeds of up to $341,438 upon the Selling Stockholder’s ex
• $22.16 — th a weighted average exercise price of $22.16 per share; 364,072 shares of common s
• $560.62 — th a weighted average exercise price of $560.62 per share; 443,585 shares of common s
• $2.00 — th a weighted average exercise price of $2.00 per share; 13,995,183 shares of commo
• $10 million — estment Right”) to purchase up to $10 million of aggregate stated value of additional
• $200,000 — nly be exercised in a minimum amount of $200,000 of AIR Preferred Shares. The actual num
• $10 m — Actual gross proceeds may be less than $10 million, which may impact our future liqu
• $0.612 — ficate of Designation, currently set at $0.612 per share) and (y) 85% of the arithmeti

Filing Documents

• forms-1.htm (S-1) — 319KB
• ex5-1.htm (EX-5.1) — 25KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 22KB
• forms-1_001.jpg (GRAPHIC) — 6KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• ex23-1_001.jpg (GRAPHIC) — 5KB
• 0001493152-25-018032.txt ( ) — 516KB
• ex107_htm.xml (XML) — 7KB

USE OF PROCEEDS

USE OF PROCEEDS 5 DIVIDEND POLICY 5

DESCRIPTION OF SECURITIES THAT THE SELLING STOCKHOLDER IS OFFERING

DESCRIPTION OF SECURITIES THAT THE SELLING STOCKHOLDER IS OFFERING 5 SELLING STOCKHOLDER 7 PLAN OF DISTRIBUTION 8 LEGAL MATTERS 10 EXPERTS 10 WHERE YOU CAN FIND MORE INFORMATION 10 INCORPORATION OF DOCUMENTS BY REFERENCE 11 PROSPECTUS SUMMARY The SEC allows us to “incorporate by reference” certain information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will update automatically, supplement, and/or supersede the information disclosed in this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other document that also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should read the entire prospectus carefully, including the matters set forth under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our financial statements, and related notes included elsewhere in this prospectus and the information incorporated into this prospectus by reference . In this prospectus, unless context requires otherwise, references to “we,” “us,” “our,” “INVO Fertility,” “INVO,” or “the Company” refer to INVO Fertility, Inc. and its subsidiaries. The Company We are a healthcare services and technology company focused on the fertility marketplace and dedicated to

View Full Filing

View this S-1 filing on SEC EDGAR